Organ-on-a-Chip Patent Landscape 2026
Organ-on-a-Chip Patent Landscape in 2026
The organ-on-a-chip field is concentrated among a small set of academic spinouts and research universities, with Emulate Inc holding a commanding lead and the top five filers collectively dominating the hundred largest filers. Annual filing volume peaked in 2021 and has eased since, a pattern consistent with a maturing core technology base rather than waning interest.
Emulate Inc leads a university-heavy field with a clear tier gap
Emulate Inc sits atop
The top five filers — Emulate Inc, Harvard, Vanderbilt University, MIT, and TissUse GmbH — account for 35% of the combined output of the hundred largest filers, signaling a moderately concentrated field where a handful of players set the technical agenda while a long tail of academic institutions contributes incremental work.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | Emulate Inc | 276 | |
| 2 | PRESIDENT & FELLOWS OF HARVARD COLLEGE | 185 | |
| 3 | Vanderbilt University | 71 | |
| 4 | Massachusetts Institute of Technology | 64 | |
| 5 | TissUse GmbH | 61 | |
| 6 | University of Central Florida Research Foundation | 46 | |
| 7 | National Institute of Advanced Industrial Science and Technology (AIST) | 42 | |
| 8 | The Trustees of the University of Pennsylvania | 40 | |
| 9 | Wake Forest University Health Sciences | 39 | |
| 10 | Koninklijke Philips N.V. | 35 |
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 11 | Javelin Biotech Inc | 30 | |
| 12 | Cedars-Sinai Medical Center | 29 | |
| 13 | Centre National de la Recherche Scientifique (CNRS) | 29 | |
| 14 | Regents of the University of California | 29 | |
| 15 | Fraunhofer-Gesellschaft | 26 | |
| 16 | LUMICKS CA Holding B.V. | 26 | |
| 17 | Yissum Research Development Company of the Hebrew University of Jerusalem | 25 | |
| 18 | Axosim Inc | 21 | |
| 19 | Fluigent | 20 | |
| 20 | The Governing Council of the University of Toronto | 19 |
Emulate’s position reflects its origin as the primary Harvard spinout in this space; the strong showing of Vanderbilt, MIT, and the University of Pennsylvania confirms that research universities remain the dominant innovation engines, with European industrial players such as TissUse and Koninklijke Philips providing a smaller but distinct corporate counterweight.
Filing counts for 2024 and especially 2025–2026 are under-counted due to typical 18–24 month publication lags and should not be read as evidence of further decline. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2021 peak in annual filings, with bioreactor apparatus dominating the technology mix
The filing trend and the IPC composition together reveal a field whose foundational platform claims are largely staked and whose remaining white space lies in application-layer and downstream IPC classes.
Annual filing trend
Annual filings rose from 2017 to a peak of 267 in 2021, then eased to 233 in 2022 and 206 in 2023. The apparent further drop in 2024–2026 reflects publication lag and should not be interpreted as acceleration of the decline; the underlying trend is best read as post-peak stabilization.
↗ Hover for values · click a bar to ask EurekaTechnology composition
C12M (bioreactors and enzyme apparatus) and G01N (material analysis and testing) together account for the largest share of classified records, confirming that the IP estate is still anchored in device architecture and assay readout. Lower-density branches such as A61K (medicinal preparations), A61P (therapeutic activity), and B33Y (additive manufacturing) suggest that translational and fabrication-oriented claiming remains relatively sparse.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Human organ-on-a-chip having reverse micro-weir st…
The present invention relates to an organ-on-a-chip having a reverse micro-weir structure and uses thereof. Using the organ-on-a-chip for evaluating drug efficacy and toxicity provided by the present invention makes it possible to overcome the limitations of conventional two-dimensional in-vitro cell culture methods that cannot mimic the human… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Vascularized perfused microtissue/micro-organ arrays | 775 |
| 2 | Slippery surfaces with high pressure stability, op… | 334 |
| 3 | Instrument for constructing tissue arrays | 219 |
| 4 | Perfused three-dimensional cell/tissue disease mod… | 203 |
| 5 | Organ chips and uses thereof | 184 |
| 6 | Perfused three-dimensional cell/tissue disease mod… | 141 |
| 7 | Low shear microfluidic devices and methods of use … | 130 |
| 8 | Integrated human organ-on-chip microphysiological … | 130 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents.
What the competitive structure means for R&D investment decisions
Four structural observations — maturity stage, concentration, collaboration patterns, and geographic spread — shape where new entrants can realistically compete and where incumbents are most defensible.
Post-peak: core platform IP is largely staked
The lifecycle evidence places the field in a decline stage, with annual filings having eased back from their 2021 peak. This does not mean the commercial opportunity is closed, but it does mean that undifferentiated platform claims in bioreactor apparatus and microfluidic device architecture face a crowded prior-art landscape. R&D investment is better directed toward application-specific claiming — disease modeling, drug screening assay integration — where headroom remains.
Lifecycle: DeclineTop five hold 35% of the hundred largest filers’ output
The field is moderately concentrated. Emulate Inc’s lead of 276 patent families versus Harvard’s 185 creates a meaningful gap at the top, but ranks 3–10 (Vanderbilt at 71, MIT at 64, TissUse at 61, and others) are closely bunched, meaning a sustained two-to-three-year filing program could shift rank positions among mid-tier players. New entrants face a high barrier in core organ-chip device claims but a lower barrier in downstream application classes.
Concentration: ModerateEmulate–Janssen Biotech is the field’s most active co-filing pair
The strongest co-filing relationship is between Emulate Inc and Janssen Biotech Inc, with 28 jointly filed patent families, reflecting a pharma-platform partnership model. Harvard and Children’s Medical Center Corporation follow with 14 co-filed families, illustrating academic-hospital collaboration. The University of Central Florida Research Foundation has formed separate co-filing arrangements with both Axosim Inc (13 families) and Hesperos Inc (8 families), indicating that mid-tier universities are building startup ecosystems around their organ-chip platforms. MIT and the University of Pittsburgh account for 9 co-filed families, adding another academic-academic axis.
Collaboration: ActiveUS-centric filing with PCT and EPO as the main secondary routes
The United States leads all jurisdictions in patent records, followed by WIPO PCT filings and the European Patent Office. China ranks fourth, indicating growing but not yet dominant Asian interest. Japan, Canada, and Australia each hold meaningful positions, while South Korea and Singapore are present but smaller. The geographic spread suggests that most major applicants pursue multi-region protection, though the depth of coverage outside the US–Europe–PCT triad drops sharply.
Geography: US-ledGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Emulate Inc | Janssen Biotech Inc | 28 |
| President & Fellows of Harvard College | Children’s Medical Center Corporation | 14 |
| University of Central Florida Research Foundation | Axosim Inc | 13 |
| Massachusetts Institute of Technology | University of Pittsburgh | 9 |
| Emulate Inc | Cedars-Sinai Medical Center | 8 |
| University of Central Florida Research Foundation | Hesperos Inc | 8 |
| National Institute of Advanced Industrial Science and Technology (AIST) | Tokyo Ohka Kogyo Co., Ltd. | 7 |
| University of Central Florida Research Foundation | Administrators of the Tulane Educational Fund | 3 |
| The Trustees of the University of Pennsylvania | Children’s Hospital of Philadelphia | 3 |
| Emulate Inc | F. Hoffmann-La Roche AG | 2 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Emulate Inc leads on volume; Harvard maintains the broadest platform breadth
The two largest filers share a common technical foundation in bioreactor apparatus and lab device claims but differ in trajectory: Emulate’s recent output has contracted sharply while Harvard’s has remained relatively stable.
Emulate Inc
Emulate Inc holds 276 patent families, the largest position in the field. Its technology emphasis spans bioreactor apparatus (C12M 3 and C12M 1) and material analysis and testing (G01N 33), reflecting a full-stack organ-chip platform strategy covering device design, fluidics, and assay readout. Recent momentum shows a sharp contraction (▼ –70% versus the prior three-year window), consistent with a company that has built out its core IP estate and is now deploying rather than expanding it. The active co-filing relationship with Janssen Biotech Inc (28 joint families) confirms a pharma-validation commercialization path.
families: 276President & Fellows of Harvard College
Harvard holds 185 patent families, second in the ranking, and maintains the broadest lab-apparatus footprint (B01L 3 at 91 records) alongside bioreactor and analysis claims. Its recent filing trend is essentially flat (▬ –5%), making it the most stable filer among the top applicants and the strongest institutional counterweight to Emulate’s commercial lead. The 14 co-filed families with Children’s Medical Center Corporation point to translational research partnerships that could yield new application-layer claims.
families: 185| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Emulate Inc | 25 | ▼ -70% |
| President & Fellows of Harvard College | 20 | ▬ -5% |
| Vanderbilt University | 7 | ▼ -70% |
| Massachusetts Institute of Technology | 7 | ▼ -42% |
| University of Central Florida Research Foundation | 10 | ▼ -52% |
| National Institute of Advanced Industrial Science and Technology (AIST) | 5 | ▲ new entrant |
| The Trustees of the University of Pennsylvania | 12 | ▼ -14% |
| Wake Forest University Health Sciences | 3 | ▲ new entrant |
Under-served branches adjacent to the dominant organ-chip core
Several IPC branches appear at notably lower densities relative to the field’s total, pointing to areas where patent coverage is thin and where technical adjacency to organ-on-a-chip is plausible. These are observations of relative sparsity; they are only opportunities if the technical fit and entry path are validated by further search.
A61K · Medicinal preparations — drug-loading and formulation claims
With 153 records against the field’s dominant C12M backbone, medicinal-preparation claiming in the organ-chip context is sparse. Organ chips are increasingly used as pharmacokinetic and toxicology screening tools, yet IP specifically covering drug formulation protocols optimized for chip-based delivery and metabolism readout remains thin. An entrant with pharma formulation expertise could file in this branch by combining existing chip-perfusion methods with novel compound-loading or carrier-material claims, provided freedom-to-operate in the core fluidic device layer is confirmed.
Search this in Eureka →B33Y · Additive manufacturing (3D printing) for organ-chip fabrication
Additive manufacturing appears in only 63 records, a low share given the growing use of bioprinting and multi-material 3D printing in chip fabrication. The technical value is concrete: 3D printing enables complex vascular geometries and gradient scaffolds that conventional PDMS soft lithography cannot easily replicate. The entry path involves claiming novel print-process parameters, ink compositions, or post-print surface-functionalization steps specific to organ-chip performance criteria, a space distinct from the broader bioprinting literature.
Search this in Eureka →How the leading filers differ across technology routes
Strength of each leader across the main technology routes.
| Player | C12M 1 · Bioreactors & enzyme apparatus | C12M 3 · Bioreactors & enzyme apparatus | G01N 33 · Material analysis & testing | B01L 3 · Lab apparatus | C12N 5 · Microorganisms & genetic engineering |
|---|---|---|---|---|---|
| Emulate Inc | Strong · 172 | Strong · 181 | Strong · 162 | Strong · 155 | Strong · 133 |
| President & Fellows of Harvard College | Strong · 78 | Strong · 100 | Strong · 65 | Strong · 91 | Strong · 51 |
| Vanderbilt University | Strong · 51 | Strong · 53 | Moderate · 19 | Strong · 49 | Absent |
| Massachusetts Institute of Technology | Strong · 43 | Moderate · 21 | Strong · 23 | Strong · 33 | Absent |
| National Institute of Advanced Industrial Science and Technology (AIST) | Strong · 42 | Strong · 35 | Absent | Absent | Strong · 25 |
| TissUse GmbH | Absent | Strong · 35 | Strong · 27 | Strong · 22 | Moderate · 16 |
| The Trustees of the University of Pennsylvania | Strong · 28 | Strong · 28 | Absent | Absent | Strong · 19 |
Frequently asked questions
Emulate Inc leads with 276 patent families, followed by the President & Fellows of Harvard College with 185. The gap between first and second place is larger than any other consecutive gap in the top ten, giving Emulate a structural lead that has not been closed by any single challenger.
Annual filings peaked at 267 in 2021 and have eased since, reaching 206 in 2023. The lifecycle evidence characterizes the field as post-peak. The apparent further drop in 2024 and 2025 data is attributable to publication lag and does not necessarily reflect continued decline.
The United States leads in patent records, followed by WIPO PCT filings and the European Patent Office. China ranks fourth. These four jurisdictions together cover the bulk of protection activity; Japan, Canada, and Australia are secondary but meaningful markets.
C12M (bioreactors and enzyme apparatus) and G01N (material analysis and testing) account for the largest record counts, reflecting a field still centered on device architecture and assay readout. B01L (lab apparatus) and C12N (microorganisms and genetic engineering) are the next largest branches.
Emulate Inc and Janssen Biotech Inc have the largest co-filing relationship in the corpus at 28 jointly filed families. Harvard and Children’s Medical Center Corporation follow with 14, and the University of Central Florida Research Foundation co-files with both Axosim Inc (13 families) and Hesperos Inc (8 families).
The branches with the lowest record density relative to the dominant core include A61K (medicinal preparations), A61P (therapeutic activity of compounds), A01N (biocides and agrochemicals), and B33Y (additive manufacturing). These reflect areas where the connection to organ-chip platforms is technically plausible but claiming activity is sparse, making them candidates for targeted IP development, subject to freedom-to-operate review.
Ready to map your own organ-on-a-chip landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.